Phase IV, Single Arm Study of Safety and Efficacy of Everolimus in Chinese Adults With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma Not Requiring Immediate Surgery
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Everolimus (Primary)
- Indications Angiomyolipoma
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 14 Oct 2019 Planned End Date changed from 6 Jan 2022 to 26 Oct 2020.
- 14 Oct 2019 Planned primary completion date changed from 6 Jan 2022 to 26 Oct 2020.
- 14 Oct 2019 Status changed from recruiting to active, no longer recruiting.